# Immunogenicity, safety, and reactogenicity of heterolo
# incorporating mRNA, viral-vector, and protein-adjuvan
# single-blind, randomised, phase 2, non-inferiority trial

Lancet, The

399, 36-49

DOI: 10.1016/s0140-6736(21)02718-5

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 3 | Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 2258-2276. | 13.7 | 519 |
| 4 | Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19. Lancet, The, 2022, 399, 3-5. | 13.7 | 3 |
| 5 | Adenovirus-based vaccinesâ€"a platform for pandemic preparedness against emerging viral pathogens. Molecular Therapy, 2022, 30, 1822-1849. | 8.2 | 24 |
| 6 | Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. Cells, 2022, 11, 465. | 4.1 | 3 |
| 7 | Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet, The, 2022, 399, 234-236. | 13.7 | 318 |
| 8 | Simple Vaccination Is not Enough for the Transplant Recipient. Transplantation, 2022, 106, 447-448. | 1.0 | 9 |
| 9 | Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies. Vaccines, 2022, 10, 151. | 4.4 | 6 |
| 11 | The T cell immune response against SARS-CoV-2. Nature Immunology, 2022, 23, 186-193. | 14.5 | 785 |
| 12 | What the Omicron wave is revealing about human immunity. Nature, 2022, 602, 22-25. | 27.8 | 35 |
| 13 | Covid-19: â€œMix and matchâ€•primary vaccines are safe and effective, study finds. BMJ, The, 2021, 375, n3030. | 6.0 | 1 |
| 14 | Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. Vaccines, 2022, 10, 359. | 4.4 | 11 |
| 15 | Reactogenicity among health care workers following a BNT162b2 or mRNA-1273Âsecond dose after priming with a ChAdOx1 nCOV-19 vaccine. Clinical Microbiology and Infection, 2022, , . | 6.0 | 1 |
| 16 | COVID-19 vaccination in patients with cancer, a rapid review. Ecancermedicalscience, 2022, 16, 1355. | 1.1 | 4 |
| 17 | mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. Human Vaccines and Immunotherapeutics, 2022, 18, 2040330. | 3.3 | 5 |
| 18 | COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies. Viruses, 2022, 14, 573. | 3.3 | 38 |
| 19 | â€œIs Omicron mildâ€? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies. Journal of Medical Virology, 2022, 94, 3521-3539. | 5.0 | 20 |
| 20 | The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines. Vaccines, 2022, 10, 506. | 4.4 | 4 |
| 21 | COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nature Reviews Clinical Oncology, 2022, 19, 385-401. | 27.6 | 135 |

| # | Article | IF | Citations |
|---|---|---|---|
| 22 | Immune responses against different variants of SARS-CoV-2 including Omicron following 6Âmonths of administration of heterologous prime-boost COVID-19 vaccine. Journal of Travel Medicine, 2022, 29, . | 3.0 | 9 |
| 23 | Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination. Vaccines, 2022, 10, 491. | 4.4 | 4 |
| 24 | COVID-19 vaccine results might inform malaria vaccine strategies. Lancet Infectious Diseases, The, 2022, 22, 440-441. | 9.1 | 1 |
| 25 | Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. Lancet Microbe, The, 2022, 3, e252-e264. | 7.3 | 29 |
| 26 | Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine. Vaccines, 2022, 10, 754. | 4.4 | 10 |
| 27 | Random Copolymers of Lysine and Isoleucine for Efficient mRNA Delivery. International Journal of Molecular Sciences, 2022, 23, 5363. | 4.1 | 3 |
| 28 | Acute reactions after vaccination against COVID-19 and long-term antibody levels. Deutsches Ärzteblatt International, 0, , . | 0.9 | 0 |
| 29 | Antibody-mediated neutralization of SARS-CoV-2. Immunity, 2022, 55, 925-944. | 14.3 | 74 |
| 30 | Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nature Communications, 2022, 13, 2670. | 12.8 | 108 |
| 31 | Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2. Vaccines, 2022, 10, 788. | 4.4 | 2 |
| 32 | Vaccine pragmatism in the 21st century. Lancet Infectious Diseases, The, 2022, , . | 9.1 | 0 |
| 33 | Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. PLoS Medicine, 2022, 19, e1003953. | 8.4 | 27 |
| 34 | Viral vector vaccines. Current Opinion in Immunology, 2022, 77, 102210. | 5.5 | 28 |
| 35 | Immunogenicity of COVID-19 Vaccination in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis: The Efficacy of a Mix-and-Match Strategy. Journal of Korean Medical Science, 2022, 37, . | 2.5 | 7 |
| 36 | COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 176-188. | 3.8 | 7 |
| 37 | Benefitâ€“risk evaluation of COVID-19 vaccination in special population groups of interest. Vaccine, 2022, 40, 4348-4360. | 3.8 | 5 |
| 38 | Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies. Biomedicines, 2022, 10, 1260. | 3.2 | 6 |
| 39 | Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ, The, 0, , e069989. | 6.0 | 78 |

| # | Article | IF | Citations |
|---|---|---|---|
| 40 | Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 nCov-19 Determined Using Three SARS-CoV-2 Antibody Assays and an Interferon-Gamma Release Assay: A Prospective Longitudinal Study in Healthcare Workers. Frontiers in Immunology, 2022, 13, . | 4.8 | 7 |
| 41 | Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respiratory Medicine,the, 2022, 10, 739-748. | 10.7 | 82 |
| 42 | Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. Lancet Respiratory Medicine,the, 2022, 10, 1049-1060. | 10.7 | 24 |
| 43 | Adverse Reactions of COVID-19 Vaccines. Journal of Clinical Otolaryngology, 2022, 33, 92-104. | 0.1 | 1 |
| 45 | Short-sighted decision-making by those not vaccinated against COVID-19. Scientific Reports, 2022, 12, . | 3.3 | 5 |
| 46 | Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization. Clinical Microbiology and Infection, 2022, 28, 1316-1318. | 6.0 | 1 |
| 47 | Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study. BMJ, The, 0, , e070483. | 6.0 | 7 |
| 48 | Durability of Humoral and Cellular Immunity after an Extended Primary Series with Heterologous Inactivated SARS-CoV-2 Prime-Boost and ChAdOx1 nCoV-19 in Dialysis Patients (ICON3). Vaccines, 2022, 10, 1064. | 4.4 | 6 |
| 49 | Cutaneous adverse reactions following <scp>SARSâ€CoV</scp>â€2 vaccine booster dose: a realâ€life multicentre experience. Journal of the European Academy of Dermatology and Venereology, 2022, 36, . | 2.4 | 18 |
| 50 | Advances in COVID-19 Vaccines and New Coronavirus Variants. Frontiers in Medicine, 0, 9, . | 2.6 | 4 |
| 51 | Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2. Vaccine, 2022, 40, 5189-5196. | 3.8 | 9 |
| 52 | Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. International Journal of Biological Sciences, 2022, 18, 4629-4641. | 6.4 | 24 |
| 54 | Skin reaction after <scp>SARSâ€CoV</scp>â€2 vaccines Reply to â€˜cutaneous adverse reactions following <scp>SARSâ€CoV</scp>â€2 vaccine booster dose: A realâ€life multicentre experienceâ€™. Journal of the European Academy of Dermatology and Venereology, 2023, 37, . | 2.4 | 21 |
| 55 | Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study. Vaccine, 2022, 40, 5701-5708. | 3.8 | 0 |
| 56 | Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. Nature Communications, 2022, 13, . | 12.8 | 33 |
| 57 | Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers. Vaccine, 2022, 40, 5445-5451. | 3.8 | 3 |
| 58 | Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273. Cell Reports Medicine, 2022, 3, 100706. | 6.5 | 23 |
| 59 | Immunogenicity of <scp>COVID</scp>â€19 vaccines in chronic liver disease patients and liver transplant recipients: A systematic review and metaâ€analysis. Liver International, 2023, 43, 34-48. | 3.9 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 60 | Protein-based vaccine as the booster dose for adults: evidence and beyond. Lancet Infectious Diseases, The, 2022, 22, 1515-1517. | 9.1 | 3 |
| 61 | The current status of COVID-19 vaccines. A scoping review. Drug Discovery Today, 2022, 27, 103336. | 6.4 | 7 |
| 62 | Self-reported reactogenicity after different COVID-19 vaccination regimensâ€"an analysis of registry-based data. Deutsches Ärzteblatt International, 0, , . | 0.9 | 2 |
| 63 | SARS-CoV-2 immunity and vaccine strategies in people with HIV. Oxford Open Immunology, 2022, 3, . | 2.8 | 12 |
| 64 | A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19. Nature Communications, 2022, 13, . | 12.8 | 13 |
| 65 | Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. Journal of Drug Delivery Science and Technology, 2022, 76, 103762. | 3.0 | 0 |
| 66 | Safety and Efficacy of the Two Doses Conjugated Protein-Based SOBERANA-02 COVID-19 Vaccine and of a Heterologous Three-Dose Combination with SOBERANA-PLUS: Double-Blind, Randomised, Placebo-Controlled Phase 3 Clinical Trial. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 67 | Metabolomics-based investigation of SARS-CoV-2 vaccination (Sinovac) reveals an immune-dependent metabolite biomarker. Frontiers in Immunology, 0, 13, . | 4.8 | 5 |
| 68 | Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nature Communications, 2022, 13, . | 12.8 | 42 |
| 70 | Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study. Vaccines, 2022, 10, 1497. | 4.4 | 7 |
| 72 | Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results. Npj Vaccines, 2022, 7, . | 6.0 | 3 |
| 73 | Coronavirus Vaccination: Spike Antibody Levels in Health Workers after Six Monthsâ€"A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 11422. | 2.6 | 1 |
| 74 | Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines. Journal of Rheumatology, 2022, 49, 1385-1389. | 2.0 | 9 |
| 75 | â€˜Mix and Matchâ€™ vaccination: Is dengue next?. Vaccine, 2022, 40, 6455-6462. | 3.8 | 0 |
| 76 | Tissue resident memory T cells- A new benchmark for the induction of vaccine-induced mucosal immunity. Frontiers in Immunology, 0, 13, . | 4.8 | 15 |
| 77 | Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nature Medicine, 2023, 29, 147-157. | 30.7 | 32 |
| 78 | Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vaccines, 2022, 10, 1751. | 4.4 | 10 |
| 79 | COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. Journal of Biomedical Science, 2022, 29, . | 7.0 | 77 |

| # | Article | IF | Citations |
|---|---|---|---|
| 81 | Reactogenicity and Humoral Immune Response after Heterologous Vaxzevria/Comirnaty Vaccination in a Group of Individuals Vaccinated in the AOU Policlinic â€œG. Martinoâ€•(Messina, Italy): A Retrospective Cohort Study. Vaccines, 2022, 10, 1803. | 4.4 | 0 |
| 82 | Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet, The, 2022, 400, 1305-1320. | 13.7 | 112 |
| 83 | Emerging features of MAIT cells and other unconventional T cell populations in human viral disease and vaccination.. Seminars in Immunology, 2022, 61-64, 101661. | 5.6 | 8 |
| 84 | MULTI-PARAMETRIC PREDICTION MODELS FOR COVID-19 VACCINE SELECTION: RESULTS OF A COMPARATIVE POPULATION-BASED COHORT STUDY. Clinical Infectious Diseases, 0, , . | 5.8 | 0 |
| 85 | Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunity. Vaccine, 2022, 40, 6864-6872. | 3.8 | 1 |
| 86 | Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations. Vaccines, 2022, 10, 1869. | 4.4 | 1 |
| 87 | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What. Vaccines, 2022, 10, 1924. | 4.4 | 8 |
| 88 | Correlation between Clinical and Immunological Variables and Humoral Response to SARS-CoV-2 Vaccination in Adult Patients with Antibody Deficiency Disorders. Pathogens, 2022, 11, 1364. | 2.8 | 1 |
| 90 | COVID-19 in kidney transplantation-implications for immunosuppression and vaccination. Frontiers in Medicine, 0, 9, . | 2.6 | 2 |
| 91 | COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia. HemaSphere, 2023, 7, e811. | 2.7 | 6 |
| 92 | Multipolymer microsphere delivery of SARS-CoV-2 antigens. Acta Biomaterialia, 2023, 158, 493-509. | 8.3 | 4 |
| 93 | Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses. Emerging Microbes and Infections, 2023, 12, . | 6.5 | 2 |
| 95 | Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles. IScience, 2023, 26, 105862. | 4.1 | 8 |
| 98 | Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape. Human Vaccines and Immunotherapeutics, 2023, 19, . | 3.3 | 8 |
| 99 | Hybrid and herd immunity 6Âmonths after SARS-CoV-2 exposure among individuals from a community treatment program. Scientific Reports, 2023, 13, . | 3.3 | 10 |
| 100 | Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial. The Lancet Regional Health Americas, 2023, 18, 100423. | 2.6 | 16 |
| 101 | Preliminary In Vivo Evidence of Oral Selenium Supplementation as a Potentiating Agent on a Vector-Based COVID-19 Vaccine in BALB/c Mice. Vaccines, 2023, 11, 57. | 4.4 | 1 |
| 102 | Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis. Chinese Medical Journal, 2023, 136, 24-33. | 2.3 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 104 | Detailed characterization of SARS-CoV-2-specific T and B cells after infection or heterologous vaccination. Frontiers in Immunology, 0, 14, . | 4.8 | 4 |
| 105 | Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study. Biomedicines, 2023, 11, 511. | 3.2 | 3 |
| 106 | Comparison of humoral and cellular immune responses between ChAd-BNT heterologous vaccination and BNT-BNT homologous vaccination following the third BNT dose: A prospective cohort study. Frontiers in Immunology, 0, 14, . | 4.8 | 8 |
| 107 | Effectiveness of mRNA and viralâ€vector vaccines in epidemic period led by different SARSâ€CoVâ€2 variants: A systematic review and metaâ€analysis. Journal of Medical Virology, 2023, 95, . | 5.0 | 3 |
| 108 | Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. Lancet Respiratory Medicine,the, 2023, 11, 613-623. | 10.7 | 14 |
| 109 | SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity. Frontiers in Immunology, 0, 14, . | 4.8 | 1 |
| 110 | Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5â€included SARSâ€CoVâ€2 variants than homologous vaccination of mRNA vaccine. MedComm, 2023, 4, . | 7.2 | 2 |
| 111 | BMI-Associated Anti-Apolipoprotein A-1 Positivity in Healthy Adults after mRNA-Vaccination against COVID-19. Vaccines, 2023, 11, 670. | 4.4 | 1 |
| 112 | COVID-19 Disease in Under-5 Children: Current Status and Strategies for Prevention including Vaccination. Vaccines, 2023, 11, 693. | 4.4 | 3 |
| 113 | Consistent neutralization of circulating omicron subâ€variants by hybrid immunity up to 6 months after booster vaccination. Journal of Medical Virology, 2023, 95, . | 5.0 | 2 |
| 114 | SARS-CoV-2 specific T-cell humoral response assessment after COVID-19 vaccination using a rapid direct real-time PCR amplification. Clinical Chemistry and Laboratory Medicine, 2023, 61, 1652-1660. | 2.3 | 3 |
| 115 | Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain. Nature Communications, 2023, 14, . | 12.8 | 6 |
| 116 | Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study â€“ A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines. Journal of Infection, 2023, , . | 3.3 | 3 |
| 117 | Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial. Vaccine, 2023, 41, 3497-3505. | 3.8 | 3 |
| 118 | Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan. Human Vaccines and Immunotherapeutics, 2023, 19, . | 3.3 | 0 |
| 119 | Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. Lancet Regional Health - Europe, The, 2023, 28, 100613. | 5.6 | 6 |
| 120 | A study of glycemic perturbations following two doses of COVID-19 vaccination for patients with diabetes: the impacts of vaccine type and anti-diabetes drugs. Diabetology and Metabolic Syndrome, 2023, 15, . | 2.7 | 1 |
| 121 | Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021. Human Vaccines and Immunotherapeutics, 2023, 19, . | 3.3 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 122 | GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial. Cell Reports Medicine, 2023, 4, 101084. | 6.5 | 2 |
| 123 | Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study. BMJ Open, 2023, 13, e071397. | 1.9 | 3 |
| 124 | Aiming to Improve Racial and Ethnic Representation in COVID-19 Trials. JAMA Internal Medicine, 0, , . | 5.1 | 0 |
| 125 | Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review. World Journal of Diabetes, 0, 14, 892-918. | 3.5 | 2 |
| 126 | Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study. Journal of the Formosan Medical Association, 2023, , . | 1.7 | 1 |
| 127 | Omicron variant evolved: Signs, symptoms and complications. AIP Conference Proceedings, 2023, , . | 0.4 | 0 |
| 128 | Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial. Journal of Infection, 2023, 87, 230-241. | 3.3 | 3 |
| 129 | Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study. BMC Medicine, 2023, 21, . | 5.5 | 1 |
| 130 | A cohort study reveals different dynamics of SARS-CoV-2-specific antibody formation after Comirnaty and Vaxzevria vaccination. Vaccine, 2023, 41, 5037-5044. | 3.8 | 1 |
| 131 | Heterologous versus homologous boosting elicits qualitatively distinct, BA.5â€“cross-reactive T cells in transplant recipients. JCI Insight, 2023, 8, . | 5.0 | 5 |
| 132 | Flattening the Curve after the Initial Outbreak of Coronavirus Disease 2019: A Data-Driven Modeling Analysis for the Omicron Pandemic in China. Vaccines, 2023, 11, 1009. | 4.4 | 1 |
| 133 | Practical Considerations for Next-Generation Adjuvant Development and Translation. Pharmaceutics, 2023, 15, 1850. | 4.5 | 0 |
| 134 | SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine, 2023, 29, 1760-1774. | 30.7 | 27 |
| 135 | The use of RNA-based treatments in the field of cancer immunotherapy. Molecular Cancer, 2023, 22, . | 19.2 | 13 |
| 136 | NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines. Frontiers in Immunology, 0, 14, . | 4.8 | 0 |
| 137 | Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses. BMJ, The, 0, , e074325. | 6.0 | 4 |
| 138 | Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines. Revista Da Sociedade Brasileira De Medicina Tropical, 0, 56, . | 0.9 | 0 |
| 139 | A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov. Expert Review of Vaccines, 2023, 22, 704-713. | 4.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 140 | Clinical characteristics, management, and prevention of coronavirus disease 2019. Frigid Zone Medicine, 2023, 3, 134-160. | 0.3 | 0 |
| 141 | Antibody titers of individuals vaccinated forÂCOVID-19: A systematic review. Journal of Biosciences, 2023, 48, . | 1.1 | 0 |
| 142 | A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults. Scientific Reports, 2023, 13, . | 3.3 | 2 |
| 143 | Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial. EClinicalMedicine, 2023, 64, 102231. | 7.1 | 1 |
| 144 | Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial. Vaccines, 2023, 11, 1329. | 4.4 | 0 |
| 145 | Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France. Journal of Clinical Immunology, 2023, 43, 1724-1739. | 3.8 | 1 |
| 146 | An overview of protein-based SARS-CoV-2 vaccines. Vaccine, 2023, 41, 6174-6193. | 3.8 | 0 |
| 147 | Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients. Frontiers in Immunology, 0, 14, . | 4.8 | 0 |
| 148 | Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries. Vaccine, 2023, 41, 7007-7018. | 3.8 | 1 |
| 149 | Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients. Journal of Hepatology, 2024, 80, 109-123. | 3.7 | 1 |
| 150 | Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine. Scientific Reports, 2023, 13, . | 3.3 | 0 |
| 151 | Building a Better Silver Bullet: Current Status and Perspectives of Nonâ€Viral Vectors for mRNA Vaccines. Advanced Healthcare Materials, 2024, 13, . | 7.6 | 1 |
| 152 | Impact of the COVID-19 vaccine booster strategy on vaccine protection: a pilot study of a military hospital in Taiwan. Clinical and Experimental Vaccine Research, 2023, 12, 337. | 2.2 | 0 |
| 153 | Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals. PLoS Pathogens, 2023, 19, e1011744. | 4.7 | 2 |
| 154 | The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review. Journal of Infectious Diseases, 0, , . | 4.0 | 2 |
| 155 | Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials. Heliyon, 2023, 9, e22858. | 3.2 | 0 |
| 156 | Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines â€“ A prospective multi-center study. Heliyon, 2024, 10, e23246. | 3.2 | 0 |
| 157 | A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation. Npj Vaccines, 2024, 9, . | 6.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 158 | Vaccination against SARS-CoV-2 contributed to reducing the prevalence of depression in Chinese adults - A cross-sectional study. Journal of Affective Disorders, 2024, 349, 407-413. | 4.1 | 0 |
| 159 | Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study. Vaccines, 2024, 12, 83. | 4.4 | 0 |
| 160 | Development of an RBD-Fc fusion vaccine for COVID-19. Vaccine: X, 2024, 16, 100444. | 2.1 | 0 |
| 161 | Global landscape ofÂCOVID-19 research: a visualization analysis of randomized clinical trials. Clinical and Experimental Medicine, 2024, 24, . | 3.6 | 0 |